Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome

Author(s): Ioanna Gouni-Berthold, Heiner K. Berthold

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 31 , 2014

Become EABM
Become Reviewer
Call for Editor


The metabolic syndrome (MetS) is associated with a higher risk for both, type 2 diabetes mellitus and cardiovascular disease. The cornerstone of treatment is lifestyle modification, encompassing weight reduction and physical exercise. However, pharmacotherapy is usually also required to achieve the recommended target values for the various components of the MetS, such as hypertension, dysglycemia and dyslipidemia. Regarding lipid treatment, statins are the main therapeutic agents while in blood pressure control a significant amount of pathophysiological and clinical evidence would suggest the use, as first line agents, of ACE inhibitors or angiotensin receptor blockers. Metformin seems to be the drug of choice for dysglycemia, specially since recent evidence questions the safety of thiazolidinediones. New drugs, targeting multiple components of the MetS, are under development but no data are currently available regarding their long-term efficacy and safety profile. In general, a multifactorial approach is recommended to decrease cardiovascular risk in patients with the MetS.

Keywords: Dysglycemia, dyslipidemia, hypertension, hyperuricemia, metabolic syndrome, smoking.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [5025 - 5038]
Pages: 14
DOI: 10.2174/1381612819666131206111721
Price: $65

Article Metrics

PDF: 39